Bio-Techne (NASDAQ: TECH) reported Q2 EPS of $1.62, $0.25 better than the analyst estimate of $1.37. Revenue for the quarter came in at $224.3 million versus the consensus estimate of $206.48 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.